The medtech company Pexa reports decreased revenue in the fourth quarter compared with the same period the year before. The board proposes no dividend. Revenue fell to SEK 0.1 million (0.5)."Revenue has been lower than the previous year, which reflects our deliberate shift from short-term instrument sales to long-term platform building. The focus has been on building structural value in biomarker development, intellectual property, and data as a foundation for future diagnostic and clinical applications," says CEO Tomas Gustafsson. Profit after tax was SEK 0.9 million (-3). The result in the fourth quarter is positively affected by the capitalization of development costs attributable to the entire fiscal year 2025.No ordinary dividend is proposed (0). Cash flow from operating activities amounted to SEK 1.9 million (-1.9). Cash and cash equivalents amounted to SEK 6.2 million (5.6).Pexa, SEK millionQ4-2025Q4-2024Net sales0.10.5Operating profit0.9-3Net profit0.9-3Cash flow from operating activities1.9-1.9Cash and cash equivalents6.25.6Ordinary annual dividend per share, SEK00